PASADENA, Calif., May 26, 2021 – Individuals with genetic high cholesterol, heart disease or both, who were infected with COVID-19 had more heart attacks according to new research by the FH Foundation. While previous studies have speculated about poorer outcomes if a person with genetic high … Read More →
A strategic imperative of the FH Foundation is to increase FH diagnosis and improve the rate of cascade screening. We began this work in 2013 with the establishment of the CASCADE FH Registry (CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia Registry) and continue today. … Read More →
Katherine Wilemon, founder and CEO of the FH Foundation, recently authored a paper with researchers from Stanford University that highlighted key differences in care for women with familial hypercholesterolemia (FH). The paper published in Current Atherosclerosis Reports highlights the unique needs … Read More →
The Institute for Clinical and Economic Review (ICER) – an organization that produces reports that analyze the cost effectiveness of drugs and other medical services – has highlighted the improved cost-effectiveness of high cholesterol treatments inclisiran and bempedoic acid in patients who have … Read More →
We are excited to announce new data from the FH Foundation’s CASCADE FH® Registry was published in the The Journal of Pediatrics. This research helps us understand the progress that has been made in the treatment and care of children with familial hypercholesterolemia (FH) in specialty … Read More →
Increasing screening for familial hypercholesterolemia is critical for finding the 85% of individuals who are not diagnosed today. The FH Foundation leads critical research to uncover some of the barriers for cascade screening, also known as family screening, and genetic testing in the United States.
Recently, … Read More →